Spectrum Pharmaceuticals, Inc.

DB:NTR Stock Report

Market Cap: €191.1m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Spectrum Pharmaceuticals Management

Management criteria checks 1/4

Spectrum Pharmaceuticals' CEO is Tom Riga, appointed in Dec 2021, he has a tenure of 1.67 years. His total yearly compensation is $2.60M , comprised of 25% salary and 75% bonuses, including company stock and options. He directly owns 0.26% of the company’s shares, worth €489.48K. The average tenure of the management team and the board of directors is 1.5 years and 2.5 years respectively.

Key information

Tom Riga

Chief executive officer

US$2.6m

Total compensation

CEO salary percentage25.0%
CEO tenure1.7yrs
CEO ownership0.3%
Management average tenure1.5yrs
Board average tenure2.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Tom Riga's remuneration changed compared to Spectrum Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2023n/an/a

-US$68m

Dec 31 2022US$3mUS$650k

-US$78m

Sep 30 2022n/an/a

-US$106m

Jun 30 2022n/an/a

-US$117m

Mar 31 2022n/an/a

-US$138m

Dec 31 2021US$4mUS$550k

-US$158m

Sep 30 2021n/an/a

-US$169m

Jun 30 2021n/an/a

-US$184m

Mar 31 2021n/an/a

-US$166m

Dec 31 2020US$3mUS$550k

-US$171m

Sep 30 2020n/an/a

-US$162m

Jun 30 2020n/an/a

-US$140m

Mar 31 2020n/an/a

-US$136m

Dec 31 2019US$4mUS$550k

-US$135m

Sep 30 2019n/an/a

-US$148m

Jun 30 2019n/an/a

-US$191m

Mar 31 2019n/an/a

-US$147m

Dec 31 2018US$5mUS$500k

-US$127m

Sep 30 2018n/an/a

-US$102m

Jun 30 2018n/an/a

-US$51m

Mar 31 2018n/an/a

-US$87m

Dec 31 2017US$1mUS$420k

-US$101m

Compensation vs Market: Tom's total compensation ($USD2.60M) is above average for companies of similar size in the German market ($USD684.36K).

Compensation vs Earnings: Tom's compensation has been consistent with company performance over the past year.

CEO

Tom Riga (48 yo)

1.7yrs

Tenure

US$2,595,633

Compensation

Mr. Thomas J. Riga, also known as Tom, is President, Chief Executive Officer and Director at Spectrum Pharmaceuticals, Inc. since December 30, 2021. He had been the Chief Operating Officer at Spectrum Phar...

Leadership Team

NamePositionTenureCompensationOwnership
Thomas Riga
President1.7yrsUS$2.60m0.26%
€ 489.5k
Nora Brennan
Executive VP & CFO1.3yrsUS$46.25k0.051%
€ 98.3k
Keith McGahan
Executive VP5.5yrsUS$1.50m0.11%
€ 217.8k
Michael Grabow
Executive VP & Chief Business Officerless than a yearno datano data

1.5yrs

Average Tenure

48yo

Average Age

Experienced Management: NTR's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Thomas Riga
President1.7yrsUS$2.60m0.26%
€ 489.5k
Seth H. Fischer
Independent Director3.3yrsUS$178.83k0.0020%
€ 3.8k
William Ashton
Independent Chairman of the Board5.5yrsUS$202.58k0.021%
€ 40.0k
Jeffrey Vacirca
Independent Director4.8yrsUS$181.33k0.13%
€ 253.4k
Brittany Bradrick
Independent Director1.3yrsUS$158.53kno data
Juhyun Lim
Director1.4yrsUS$183.93k0.0023%
€ 4.5k

2.5yrs

Average Tenure

53.5yo

Average Age

Experienced Board: NTR's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/08/01 09:10
End of Day Share Price 2023/07/31 00:00
Earnings2023/03/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Spectrum Pharmaceuticals, Inc. is covered by 17 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Difei YangAuriga USA LLC
David BuckB. Riley Securities, Inc.
Alethia YoungCantor Fitzgerald & Co.